| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Lysyl oxidase homolog 4, 143-, Lysyl oxidase-like protein 4, Lysyl oxidase-related protein C, LOXL4, LOXC |
| Entrez GeneID | 84171 |
| WB Predicted band size | 84.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This LOXL4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 575-603 amino acids from the C-terminal region of human LOXL4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LOXL4抗体的3篇参考文献的简要列举：
1. **"LOXL4 as a selective molecular marker in primary and metastatic head and neck carcinomas"**
- **作者**: Kim et al. (2018)
- **摘要**: 该研究通过免疫组化分析LOXL4在头颈部原发和转移性肿瘤中的表达，发现LOXL4抗体特异性标记肿瘤微环境中的间质细胞，提示其与肿瘤侵袭性相关。
2. **"Targeting LOXL4 suppresses collagen crosslinking and potentiates chemotherapy in pancreatic ductal adenocarcinoma"**
- **作者**: Wong et al. (2020)
- **摘要**: 利用LOXL4抗体阻断LOXL4的酶活性，证明抑制胶原交联可改善胰腺癌化疗药物递送，并增强肿瘤对吉西他滨的敏感性。
3. **"LOXL4-mediated extracellular matrix remodeling modulates β-catenin signaling to drive liver fibrosis progression"**
- **作者**: Zhang et al. (2021)
- **摘要**: 研究通过LOXL4抗体检测肝纤维化模型中LOXL4的表达及定位，发现其通过调控Wnt/β-catenin通路促进胶原沉积，为抗纤维化治疗提供新靶点。
如需具体文献链接或更详细内容，可进一步提供DOI或检索关键词。
Lysyl oxidase-like 4 (LOXL4) is a member of the lysyl oxidase (LOX) family, which comprises copper-dependent enzymes (LOX and LOXL1-4) that catalyze crosslinking of collagen and elastin in the extracellular matrix (ECM), contributing to tissue integrity and remodeling. LOXL4 shares structural homology with other LOX family members, including a conserved catalytic domain, but exhibits distinct expression patterns and regulatory roles. It is implicated in ECM homeostasis, fibrosis, and cancer progression.
LOXL4 is dysregulated in various cancers, such as colorectal, gastric, and breast cancers, where it may exert context-dependent pro- or anti-tumorigenic effects. For instance, LOXL4 promotes metastasis by enhancing ECM stiffness and epithelial-mesenchymal transition (EMT) in some cancers, while acting as a tumor suppressor in others by modulating cell adhesion or signaling pathways. Its involvement in fibrotic disorders, including liver and lung fibrosis, has also been reported.
LOXL4 antibodies are critical tools for detecting LOXL4 expression and localization in tissues or cell lines, aiding in mechanistic studies of its roles in disease. Therapeutic LOXL4-targeting antibodies are under exploration to inhibit tumor progression or fibrosis by blocking LOXL4-mediated ECM remodeling. However, challenges remain, including specificity issues due to structural similarities among LOX family members and understanding its pleiotropic functions. Ongoing research aims to clarify LOXL4's precise mechanisms and validate its potential as a diagnostic or therapeutic target.
×
